Established in 1998 in Shenzhen, China, Hepalink adheres to the grand vision of "bringing hope to patients, and creating value for clients".
More
The two co-founders of Hepalink are both senior experts in biosaccharide chemistry, and have in-depth understanding of the significant role of biosaccharide chemistry in immunoregulation. Immunological imbalances are the leading cause of cardiovascular disease and tumor formation, and the clinical demand for these two major diseases are left unmet.
More
After years of hard work, Hepalink has built a complete heparin industrial chain, which has become a healthy business portfolio that helps millions of global patients every year and creates steadily growing value for investors.
More
